Urovant Sciences (UROV) Short Interest Ratio & Short Volume

Short interest is the volume of Urovant Sciences shares that have been sold short but have not yet been covered or closed out. As of March 15th, traders have sold 130,700 shares of UROV short. 1.43% of Urovant Sciences' shares are currently sold short. Learn More on Urovant Sciences' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. UROV shares currently have a short interest ratio of 1.0. Learn More on Urovant Sciences's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.43% of Urovant Sciences' floating shares are currently sold short.

Urovant Sciences saw a increase in short interest in March. As of March 15th, there was short interest totaling 130,700 shares, an increase of 67.3% from the previous total of 78,100 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Urovant Sciences currently has issued a total of 32,743,000 shares. Some of Urovant Sciences' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Urovant Sciences currently has a public float of 9,130,000 shares.

1.43% of Urovant Sciences' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Urovant Sciences: Neurogene Inc. (7.87%), Arbutus Biopharma Co. (2.53%), Fulcrum Therapeutics, Inc. (3.65%), Travere Therapeutics, Inc. (13.93%), IGM Biosciences, Inc. (25.10%), Lexicon Pharmaceuticals, Inc. (8.90%), Annexon, Inc. (3.99%), KalVista Pharmaceuticals, Inc. (13.08%), Mersana Therapeutics, Inc. (8.35%), Revance Therapeutics, Inc. (13.00%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Aon plc ($5.63 billion), Charter Communications, Inc. ($5.41 billion), Analog Devices, Inc. ($5.32 billion), Baidu, Inc. ($4.45 billion), Snap Inc. ($3.86 billion), Warner Bros. Discovery, Inc. ($3.30 billion), Airbnb, Inc. ($2.82 billion), Bilibili Inc. ($2.34 billion), GameStop Corp. ($2.24 billion), and Expedia Group, Inc. ($2.21 billion). View all of the most shorted stocks.

Short selling UROV is an investing strategy that aims to generate trading profit from Urovant Sciences as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Urovant Sciences occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of UROV, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including UROV, twice per month. The most recent reporting period available is March, 15 2021.